B

BeOne

Global oncology therapeutics discovery, development, manufacturing

Senior Manager - Global Regulatory Process and Compliance

Full-Time
$139.8k - $184.8k/yr+ Annual bonus plan + Discretionary equity awards + Employee Stock Purchase Plan
Senior
Bachelor's
Remote in USA
Remote
Biology & BiotechRegulatory & Quality (Life Sciences)

About the job

Requirements
  • Proficiency with regulatory information management systems such as Veeva RIM and electronic document management systems.
  • Experience with compliance monitoring dashboards, data analytics, and reporting tools such as Power BI, Tableau, or equivalent.
  • Proficiency with the Microsoft Office Suite, including Word, Excel, PowerPoint, SharePoint, Outlook, and Teams.
  • Bachelor’s degree in Life Sciences, Regulatory Affairs, Quality, Technology, or a related discipline.
  • At least 7 years of progressive experience in Regulatory Affairs, regulatory compliance, Quality, Regulatory Operations, or another GxP function within the pharmaceutical or biotechnology industry.
  • Demonstrated experience independently leading compliance programs, risk assessments, audits or inspection-readiness activities, remediation, and cross-functional improvement initiatives.
  • Strong working knowledge of FDA, EMA, MHRA, PMDA, and other global health authority expectations, ICH guidelines, applicable GxP requirements, 21 CFR Part 11, and ALCOA+ data integrity principles.
  • Experience supporting or leading health authority inspections and internal audits.
  • Demonstrated ability to perform root-cause analysis, compliance risk assessment, trend analysis, and effectiveness monitoring.
  • Experience developing compliance KPIs, dashboards, trend analyses, and executive-level reporting.
  • Ability to translate data into actionable compliance recommendations.
  • Ability to work independently, manage competing priorities, and exercise sound judgment in a complex global environment.
Responsibilities
  • Lead regulatory compliance programs that strengthen GRA’s compliance health, inspection readiness, regulatory information management, and proactive management of regulatory risk.
  • Independently assess compliance risks and trends, develop risk-based recommendations, and lead cross-functional initiatives through implementation and effectiveness monitoring.
  • Partner across Global Regulatory Affairs and with Quality, Safety/Pharmacovigilance, Clinical, CMC, Regulatory Operations, and Regulatory Technology to keep regulatory processes, information, and supporting systems compliant, inspection-ready, and aligned with global health authority expectations.
  • Oversee Veeva RIM data stewardship and regulatory information quality, partnering with Data Management, Business Process Owners, and Data Owners/Stewards to strengthen data standards, business rules, ownership, and accountability.
  • Monitor data quality and identify and drive resolution of systemic information and process risks.
  • Lead readiness assessments, subject-matter-expert preparation, audit and inspection support, post-audit assessments, trend analysis, remediation oversight, and integration of lessons learned when Regulatory Affairs is host or in scope.
  • Conduct GRA compliance risk assessments, determine regulatory and business impact, and recommend actions to address identified risks.
  • Maintain the GRA compliance risk portfolio, including mitigation actions, owners, timelines, escalation, and effectiveness checks.
  • Assess regulatory changes, health authority expectations, audit and inspection outcomes, and internal compliance issues to determine impacts to GRA.
  • Determine whether identified issues require Quality-system action, management escalation, or process improvement, and drive the appropriate response.
  • Provide compliance guidance and appropriately challenge practices that create regulatory or inspection-readiness risk.
  • Lead GRA preparation for audits and health authority inspections where Regulatory Affairs is host or in scope.
  • Conduct readiness assessments, identify gaps, and coordinate actions needed before an audit or inspection.
  • Prepare GRA subject-matter experts through storyboards, document review, mock interviews, and inspection-readiness coaching.
  • Coordinate GRA participation in GCP, GVP, and other GxP audits and inspections with Quality and the audit or inspection host.
  • Conduct post-audit and inspection reviews to identify GRA-specific findings, recurring themes, and broader compliance risks.
  • Track GRA remediation actions through completion and confirm that actions address the identified risk.
  • Monitor critical GRA processes, including health authority questions, regulatory commitments, submissions, and regulatory information, against defined compliance requirements.
  • Establish KPIs, thresholds, and escalation triggers to identify process failures and compliance risks early.
  • Investigate recurring issues and adverse trends, determine root cause, and recommend corrective action or process improvement.
  • Work with Business Process Owners and subject-matter experts to implement actions, assign ownership, track completion, and confirm effectiveness.
  • Provide compliance oversight of regulatory information in Veeva RIM to support data quality, completeness, timeliness, traceability, and inspection readiness.
  • Lead Veeva RIM data stewardship activities, including monitoring data quality, identifying trends and recurring issues, coordinating remediation, and escalating systemic risks.
  • Partner with Data Management, Regulatory Operations, Business Process Owners, and Data Owners/Stewards to establish and maintain data standards, business rules, ownership, and accountability.
  • Monitor Veeva RIM data quality metrics and use trends to identify root causes and drive corrective actions or process improvements.
  • Assess Veeva RIM changes and enhancements for data and compliance impact and ensure appropriate business requirements and controls are addressed.
  • Develop and monitor GRA compliance KPIs, risk indicators, dashboards, and escalation thresholds.
  • Combine audit, inspection, quality, process, commitment, and regulatory information data to identify recurring and emerging compliance risks.
  • Provide GRA leadership and the Regulatory Compliance Network with clear reporting on compliance health, key risks, actions, owners, and status.
  • Use compliance data to determine whether corrective actions and improvements are working and where additional action is needed.
  • Turn audit findings, inspection lessons, compliance assessments, and monitoring results into prioritized improvement actions.
  • Lead root-cause analysis and problem-solving for significant or recurring compliance issues.
  • Develop practical guidance, tools, training, and lessons learned based on identified compliance needs.
  • Work with GRA teams and Business Process Owners to build compliance requirements into day-to-day processes and reinforce business ownership of compliance.
  • Work independently to identify, assess, and drive compliance issues to resolution.
  • Bring forward a recommended solution when escalating issues.
  • Apply sound judgment to determine risk, priority, escalation, and the appropriate course of action.
  • Lead cross-functional initiatives from problem identification through implementation and effectiveness monitoring.
  • Hold action owners accountable for agreed deliverables and timelines and escalate when needed.
  • Appropriately challenge decisions or practices that create compliance risk.
  • Communicate risks, recommendations, and decisions clearly to senior leadership.
  • Coach team members and lead employees, contractors, or project teams as assigned.
  • May manage direct reports or contractors depending on business needs.
  • Provide mentorship, coaching, and guidance to team members supporting compliance programs.
  • Collaborate closely with cross-functional peers to ensure successful execution of regulatory compliance initiatives.
Desired Qualifications
  • An advanced degree.
  • Experience with Veeva Vault RIM/BRIM or comparable Regulatory Information Management platforms.
  • RAC, ASQ CQA, Six Sigma/Lean, project management, or comparable certification.

About the company

BeOne Medicines develops and commercializes cancer therapies for patients worldwide, focusing on hematologic cancers and solid tumors. Its products, including Brukinsa, are sold globally and supported by licensing partnerships, with internal R&D and clinical development driving a broad late-stage pipeline. BeOne differentiates itself by leveraging a large-scale clinical trial network and cost-efficient global drug development to achieve high margins while pursuing large-market indications. The company aims to expand into immunology and solid tumors while maintaining strong investment in R&D to make high-impact, accessible oncology treatments available in more than 45 countries.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Dongcheng District, China

Founded

2010

Get referred to BeOne

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • August 25, 2026 FDA approval expanded TEVIMBRA in first-line HER2-positive gastroesophageal cancer.
  • August 31, 2026 Phase 3 survival data strengthened ZIIHERA-containing regimens.
  • Q2 2026 revenue hit $1.7 billion; management raised 2026 guidance to $6.8 billion.

What critics are saying

  • BeOne accepted developed-market pricing parity and Medicaid rebates on future U.S. approvals.
  • Zydus' BRUKINSA ANDA lawsuit targets patents; a 2034 composition patent remains the fortress.
  • AbbVie's trade-secrets case over BGB-16673 still threatens the BTK-degrader franchise.

What makes BeOne unique

  • BeOne built 35-plus assets and 93 trials across 1,100 U.S. sites by September 2026.
  • BRUKINSA dominates revenue, with 2026 global sales above $1.2 billion quarterly.
  • Hopewell, New Jersey gives BeOne U.S. manufacturing, R&D, and packaging capacity.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

401(k) Retirement Plan

Wellness Program

Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

8%

1 year growth

-6%

2 year growth

-1%
Associated Press
Oct 6th, 2026
Onco360 partners with BeOne Medicines to distribute Beqalzi for relapsed mantle cell lymphoma

Onco360, an independent specialty pharmacy, has been selected as a pharmacy partner by BeOne Medicines for Beqalzi (sonrotoclax). The drug is indicated for treating adults with relapsed or refractory mantle cell lymphoma after at least two lines of systemic therapy, including a Bruton's tyrosine kinase inhibitor. Beqalzi is a BCL-2 protein inhibitor. In a Phase 1/2 study of 103 adult patients with relapsed/refractory mantle cell lymphoma, the drug achieved an overall response rate of 52.4%, with a median time to response of 1.9 months. The median duration of response was 15.8 months. Onco360 is headquartered in Louisville, Kentucky, and operates as a flagship brand of PharMerica Corporation.

Yahoo Finance
Sep 4th, 2026
BeOne secures US pharma-tariff exemption after $1B+ manufacturing investment, but pricing concessions raise margin concerns

BeOne Medicines secured an exemption from Section 232 pharmaceutical tariffs through a voluntary agreement with the US government. The deal recognises over $1 billion in US manufacturing investment, including a $300 million expansion in Hopewell, New Jersey. The exemption protects BeOne from import duties on patented pharmaceuticals and ingredients. However, the company committed to pricing future FDA-approved medicines in line with other developed markets and participating in the Medicaid GENEROUS Model, which uses supplemental rebates. The Hopewell expansion will add small-molecule manufacturing and packaging capacity, creating approximately 120 full-time jobs. The facility will support a portfolio of more than 35 assets. Whilst the tariff exemption reduces supply-chain risk, international reference pricing commitments could limit pricing flexibility for future oncology medicines. Neither the tariff savings nor the financial impact of pricing concessions was disclosed.

Yahoo Finance
Aug 13th, 2026
Revolution Medicines shares rise 6.2% on BeOne-funded Phase 3 RAS(ON) deal

Revolution Medicines has partnered with BeOne Medicines in a multi-part collaboration combining BeOne's oncology assets with Revolution's four clinical RAS(ON) inhibitors. The August 2026 deal grants BeOne exclusive development and commercialisation rights in select Asian markets and commits BeOne to fund a global Phase 3 trial. Revolution Medicines reported a net loss of $644.37 million in Q2 2026 and $1.1 billion over six months. The company currently generates no revenue but projects $2.3 billion in revenue and $402.5 million in earnings by 2029. The partnership shifts near-term risk by offloading Phase 3 costs whilst providing access to milestone and royalty potential. However, the core investment case remains unchanged: regulatory progress and commercialisation of daraxonrasib, with trial execution and spending presenting the biggest risks.

Yahoo Finance
Aug 5th, 2026
BeOne Medicines Q2 revenue up 30% to $1.7B as BRUKINSA sales top $1.2B globally

BeOne Medicines reported second-quarter revenue of $1.7 billion, up 30% year over year, with GAAP earnings per ADS rising 144% to $2.05. The company's BTK inhibitor BRUKINSA generated more than $1.2 billion in global sales, increasing 31% from the prior year. The company raised its 2026 revenue guidance to CNY 6.6 billion–CNY 6.8 billion and expects GAAP operating income of CNY 1 billion–CNY 1.1 billion. Free cash flow doubled year over year to CNY 435 million. BeOne received FDA approval for Beqalzi in relapsed or refractory mantle cell lymphoma and reported positive Phase III results for a chemotherapy-free BRUKINSA regimen. US BRUKINSA sales totalled $893 million, up 31%, driven by demand in chronic lymphocytic leukaemia and non-CLL indications.

Yahoo Finance
Jul 23rd, 2026
BeOne CEO sells $34.6M in stock while retaining 50M+ shares

John Oyler, chief executive officer of BeOne Medicines AG, sold 109,713 American Depositary Shares worth $34.6 million on 20 and 21 July 2026, according to SEC filings. The transactions were executed under a Rule 10b5-1 trading plan adopted in March 2026. Despite the sale, Oyler retains a substantial ownership position exceeding 50.4 million total shares through various holdings. These include 28.2 million shares held through Oyler Investment LLC and 9.5 million shares in a Roth IRA account. The shares were sold at a weighted average price of $315.28. BeOne Medicines is a commercial-stage oncology biopharmaceutical company with $5.7 billion in trailing twelve-month revenue and a market capitalisation of $34.2 billion.